...
首页> 外文期刊>Journal of vascular surgery >Femoropopliteal prosthetic bypass with glutaraldehyde stabilized human umbilical vein (HUV).
【24h】

Femoropopliteal prosthetic bypass with glutaraldehyde stabilized human umbilical vein (HUV).

机译:用戊二醛稳定的股bypass假体旁路人脐静脉(HUV)。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Femoropopliteal bypass still is the standard surgical therapy for disabling claudication and critical ischemia. When autologous vein is not suitable synthetic or biological prostheses may be considered. Second generation glutaraldehyde tanned human umbilical vein (HUV) graft was chosen for above and below knee femoropopliteal bypass when autologous vein was not available. A single center experience regarding long-term graft function, secondary reinterventions, and potential biodegeneration of the HUV is presented. METHODS: Between January 1994 and January 2005, 211 consecutive femoropopliteal bypass operations with HUV (65 above knee and 146 below knee) were performed in 197 patients for disabling claudication (57), chronic critical ischemia (130), popliteal artery aneurysm (9), acute ischemia (14), or aneurysmal degeneration of a synthetic graft (1) in the absence of suitable ipsilateral great saphenous vein. Grafts were followed with duplex scan supplemented by additional angiography in case of recurrent ischemia with prospective documentation of follow-up data in a computerized vascular database. Surveillance of the HUV included routine evaluation of potential biodegeneration with duplex scan. Retrospective analysis of graft patency, limb salvage, and signs of aneurysmal degeneration was performed. RESULTS: Mean (median) follow-up was 44 (35) months (range 1 to 143 months). Thirty-day mortality was 2.4%. Early postoperative bypass thrombosis after a median of 4 days postoperatively (0 to 30 days) prompted revision with thrombectomy in 16% of cases. Besides late bypass thrombosis in 14.7%, additional operative or endovascular reinterventions during follow-up to maintain or restore graft patency was necessary in 8.5% of bypasses. Primary, primary assisted, secondary patency rate, and limb salvage rate after 5 years were 54%, 63%, 76%, and 92%, respectively, for all bypasses with no significant difference between above and below knee anastomosis. Duplex scan identified segmental aneurysmal degeneration in six grafts, which led to operative reintervention in three cases. The rate of detected aneurysm for grafts patent for more than three years was 7% with a rate of reintervention for aneurysm of 3.5%. CONCLUSION: Although a considerable rate of early thrombotic occlusions occurred, excellent secondary graft patency and limb salvage combined with a tolerable rate of late aneurysmal degeneration detected by means of duplex scan surveillance justify the use of the HUV in femoropopliteal bypass surgery when ipsilateral autogenous vein is not suitable.
机译:目的:股pop旁路术仍然是禁用c行和严重缺血的标准手术疗法。当自体静脉不合适时,可以考虑使用合成或生物假体。当无法获得自体静脉时,将第二代戊二醛鞣制的人脐静脉(HUV)移植物用于膝上pop下和膝下fe股旁路。介绍了有关长期移植功能,二次再介入以及HUV潜在生物变性的单一中心经验。方法:在1994年1月至2005年1月之间,对197例bling行bling行失能(57),慢性重度缺血(130),pop动脉动脉瘤(9)的患者进行了211例连续pop股静脉搭桥术(膝上65膝以下146膝)。 ,合适的同侧大隐静脉不存在时,人工移植的急性缺血(14)或动脉瘤变性(1)。在复发性缺血的情况下,移植物后进行双重扫描,辅以额外的血管造影术,并在计算机化血管数据库中对随访数据进行前瞻性记录。 HUV的监视包括常规扫描对潜在生物变性的双重扫描。回顾性分析了移植物的通畅性,肢体抢救和动脉瘤变性的迹象。结果:平均(中位)随访为44(35)个月(1到143个月)。 30天死亡率为2.4%。术后中位数为术后4天(0至30天)后的早期术后旁路血栓形成提示16%的患者行血栓切除术翻修。除14.7%的晚期旁路血栓形成外,在8.5%的旁路手术中,为维持或恢复移植物通畅,在随访期间还需要进行其他手术或血管内再干预。对于所有旁路手术,五年后的主要,主要辅助,次要通畅率和肢体挽救率分别为54%,63%,76%和92%,膝上吻合术与上下吻合术之间无显着差异。双重扫描发现了六例移植物中的节段性动脉瘤变性,其中三例导致了手术再干预。三年以上移植物专利的动脉瘤检出率为7%,对动脉瘤的再干预率为3.5%。结论:尽管发生早期血栓闭塞的发生率很高,但通过双侧扫描监测发现优良的继发移植物通畅性和肢体抢救以及可耐受的晚期动脉瘤变性的发生率,证明当同侧自体静脉为静脉时,HUV在股pop旁路手术中的应用是合理的。不合适。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号